AMSBIO offers mutant spike proteins, antigens for SARS-CoV-2 variant research
AMSBIO has introduced a collection of mutated SARS-CoV-2 spike proteins and recombinant antigens for the new virus variants – B.1.1.7 and B.1.351. These reagents can be used by researchers to evaluate the efficacy of the antibodies and identify targets for development of improved therapeutic drugs and vaccines.